← 홈

혈액암 (AML/ALL)

858개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 858개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab plus chemotherapy according to the national treatment program)

T-Lymphocytic Leukemia, Acute · T-Lymphocytic Leukemia, Acute

#T-LymphocyticLeukemiaAcute#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai General Hospital, Shan…Phase 1

Dasatinib plus anti-CD19/CD22 CAR-T cells (Dasatinib plus anti-CD19/CD22 CAR-T cells)

Ph Positive ALL; CAR-T Cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#항체#면역항체+2
효능 ORR 0%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Docetetaxel (Docetetaxel)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMasonic Cancer Center, Universi…Phase 2

Donor TCR α/β-depleted Graft/ATG (Donor TCR α/β-depleted Graft/ATG)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBaylor College of MedicinePhase 1

Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells (Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

Dose expansion: The maximum tolerated dose of CAR20.19.22 cells (Dose expansion: The maximum tolerated dose of CAR20.19.22 cells)

B-cell Non Hodgkin Lymphoma; B-cell Chronic Lymphocytic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
AntibodystaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#항체#면역항체+4
효능 ORR 88%임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

for the first 8, 21-day, cycles (Durvalumab, Durvalumab (for the first 8, 21-day, cycles))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

starting from cycle 9 (Durvalumab, Durvalumab (starting from cycle 9))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Gem/Cis)

Biliary Tract Neoplasms; Gallbladder Cancer · Biliary Tract Neoplasms

#BiliaryTractNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

28 / 43 페이지

← 이전다음 →